Full Press Release Details
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director.
LXRX
Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
Key Takeaway: Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director
Price reaction · baseline $1.67 (2024-07-05 close) · clean, no other LXRX news in the window
day 0 close · peak
-4.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus